A Single-arm, Multi-center, Phase II Exploratory Clinical Study to Evaluate the Efficacy and Safety of Trilaciclib in Preventing Myelosuppression Caused by Topoisomerase I Inhibitor Type ADC Drugs
Clinical trial NCT07736001 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT07736001
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Status
- NOT_YET_RECRUITING
- Phase
- Not Applicable
- Study type
- INTERVENTIONAL
- Start date
- 2026-07-01
- Primary completion
- 2029-07-01
- Enrollment
- 96
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.